Peripheral Neuropathy clinical trials at UC Irvine
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a randomized, double-blind, placebo-controlled adaptive study of the safety, tolerability, and exploratory efficacy of once-daily topical WST-057 administered for up to 19 weeks (or up to 24 weeks for subjects who experience a chemotherapy dose delay) to subjects who are also receiving 6 cycles (3 weeks apart) of Carboplatin AUC 5-6 and Paclitaxel 175 mg/m2 (with dose adjustment per institutional guidelines permitted).
Orange, California and other locations
Our lead scientists for Peripheral Neuropathy research studies include Jill Tseng, MD.